Pune, India, February 2022/MRFR Press Release/- Market Research Future has published its half-cooked research report on the global geographic atrophy (GA) market.
According to MRFR analysis, the global geographic atrophy (GA) market is expected to register a CAGR of 7.5% from 2021 to 2027.
The global geographic atrophy (GA) market is driven by several factors, such as the growing geriatric population and the increasing prevalence of geographic atrophy. In addition, rising R&D investments by biopharmaceutical & biotechnology companies and the introduction of novel treatment methods for geographic atrophy coupled with an increasing number of clinical trials focused on geographic atrophy is fueling the growth of the geographic atrophy (GA) market during the forecast period.
The key players are involved in new product development, strategic agreements, joint ventures, and acquisitions to augment their market positions. For instance, in July 2021, Iveric Bio (US) received an FDA agreement under Special Protocol Assessment (SPA) for the GATHER2 phase III clinical trial of zimura in geographic atrophy to age-related macular degeneration
North America is expected to dominate the geographic atrophy (GA) market, owing to the rising research activities in pharmaceutical industries and the development of new technologies for the treatment of geographic atrophy, such as stem cell therapy and gene therapy. Furthermore, the presence of major industry players such as Alkeus Pharmaceuticals, Inc. (US), Hemera Biosciences LLC (US), Apellis Pharmaceuticals, Inc. (US), and Genentech, Inc. (US) are dominating the global geographic atrophy (GA) market.
Europe is expected to hold a significant share in the global market due to the increasing older population and rising patient population. For instance, as per the World Bank, in 2020, the geriatric population over 65 years across Europe accounted for 20.78% of the total population. Thus, older people are at a higher risk of having geographic atrophy due to age-related factors. The increasing geriatric population across Europe is positively impacting the global geographic atrophy (GA) market. In addition, supportive government healthcare policies and rising pharmaceutical R&D investments are also expected to boost the market growth.
Asia-Pacific is anticipated to be the fastest-growing regional market during the forecast period due to increasing investments in healthcare infrastructure and the rising prevalence of eye disorders in the region. Moreover, global key players’ initiatives to expand operations in the Asia-Pacific region are also boosting the geographic atrophy (GA) market growth.
Furthermore, the growth of the geographic atrophy (GA) market in the rest of the world is driven by the growing geriatric population in the region, as older people are at a higher risk of having geographic atrophy. For instance, according to the United Nations (UN), the percentage of the geriatric population in Saudi Arabia will grow to an estimated 22.9% of the total population by 2050. Moreover, rising government initiatives for improving the healthcare sector and the growing number of initiatives in developing a treatment for GA in the region are also boosting the market growth.
Access full report @ https://www.marketresearchfuture.com/reports/geographic-atrophy-ga-market-10781
The global geographic atrophy (GA) market has been segmented into age group, diagnosis, and therapeutic agent’s clinical phase.
Based on age group, the market has been segmented into above 60 years and above 75 years. The above 60 years segment held a larger market share in 2020, owing to the development of geographic atrophy and other eye disorders like cataracts, dry eye, diabetic retinopathy, and glaucoma in the population above 60 years around the world.
Based on diagnosis, the market has been segmented into fundus autofluorescence (FAF), optical coherence tomography angiography (OCT-A), and multifocal electroretinography (mfERG).
Based on therapeutic agent’s clinical phase, the market has been segmented into late-stage (phase III), phase II, phase I, and pre-clinical stage & discovery candidates
Some of the key players in the global geographic atrophy (GA) market are Apellis Pharmaceuticals, Inc. (US), Iveric Bio (US), Alkeus Pharmaceuticals, Inc. (US), Hemera Biosciences LLC (US), Allegro Ophthalmics, LLC (US), Stealth BioTherapeutics (Cayman Islands), Gyroscope Therapeutics Limited (UK), Regenerative Patch Technologies, LLC (US), F. Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (US), Gensight Biologics SA (France), NGM Biopharmaceuticals Inc. (US), AstraZeneca plc (UK), Lineage Cell Therapeutics, Inc. (US), and Allergan Plc (Ireland).